Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 10;8(2):1957-1971.
doi: 10.18632/oncotarget.12699.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Marie Eliade  1 , Jeremy Skrzypski  2 , Amandine Baurand  1   2 , Caroline Jacquot  1   2 , Geoffrey Bertolone  1   2 , Catherine Loustalot  3 , Charles Coutant  3   4 , France Guy  5 , Pierre Fumoleau  6   4 , Yannis Duffourd  7 , Laurent Arnould  8 , Alexandra Delignette  9 , Marie-Martine Padéano  3 , Côme Lepage  10   11 , Géraldine Raichon-Patru  12 , Axelle Boudrant  13 , Marie-Christine Bône-Lépinoy  14 , Anne-Laure Villing  15 , Aurélie Charpin  1 , Karine Peignaux  16 , Sandy Chevrier  17 , Frédérique Vegran  17 , François Ghiringhelli  6   17 , Romain Boidot  17 , Nicolas Sevenet  18 , Sarab Lizard  8 , Laurence Faivre  1   2
Affiliations

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Marie Eliade et al. Oncotarget. .

Abstract

Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1/2 testing. Next generation sequencing and the recent discovery of new genes involved in HBOC now permit the transfer of genomic capture targeting multiple candidate genes from research to clinical use. However, the implications for the management of patients and their families have not been extensively studied, in particular since some of these genes are not well-established cancer predisposing genes. We studied 583 consecutive patients from Burgundy (France) fulfilling the criteria for BRCA testing using a next generation sequencing 25-genes panel including 20 well-established high-risk cancer genes as well as more recently identified predisposing HBOC cancer. A pathogenic BRCA1/2 mutation was found in 51 patients (9%). Besides, we found 37 pathogenic or likely pathogenic mutations in 10 different high to low-risk genes in 34 patients (6%). The most frequently mutated genes were CHEK2 (n = 12; 2%), ATM (n = 9; 1.5%), and PALB2 (n = 4; 0.6%). Three patients had a mutation in two different predisposing genes. The analysis of clinical actionability conducted in mutation-positive individuals revealed that additional disease-specific screening and/or prevention measures beyond those based on personal and family history alone had been recommended in 69% of cases. In conclusion, multigene panel testing is a powerful tool to identifying high to low-risk HBOC susceptibility genes. The penetrance and spectrum of cancers with these other genes are sometimes undefined, and further collaborative work is crucial to address this question.

Keywords: breast and ovarian cancer susceptibility genes; candidate genes; genomic capture; management; next generation sequencing.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors report no conflict of interest

Figures

Figure 1
Figure 1. Distribution of pathogenic and likely-pathogenic mutations detected in genes other than BRCA according to cancer presentation in the patient and family
In light gray, families with breast cancer presentation, and in dark grey, families with at least one patient with an ovarian cancer.
Figure 2
Figure 2. Family trees in patients with TP53 (A1), MMR gene mutations (B1-3) and variants in two predisposing genes (C1-3) (possibly including a TP53 or MMR mutation)
BC: breast cancer; OC: ovarian cancer, LiC: liver cancer, GyC: gynecological cancer, SyC: systemic cancer, PaC: pancreatic cancer, CeC: cervical cancer, PrC: prostate cancer, CRC: colorectal cancer, TeC: testis cancer, HoD: Hodgkin's disease, EC: endometrial cancer, Me: melanoma, LuC: lung cancer
Figure 2
Figure 2. Family trees in patients with TP53 (A1), MMR gene mutations (B1-3) and variants in two predisposing genes (C1-3) (possibly including a TP53 or MMR mutation)
BC: breast cancer; OC: ovarian cancer, LiC: liver cancer, GyC: gynecological cancer, SyC: systemic cancer, PaC: pancreatic cancer, CeC: cervical cancer, PrC: prostate cancer, CRC: colorectal cancer, TeC: testis cancer, HoD: Hodgkin's disease, EC: endometrial cancer, Me: melanoma, LuC: lung cancer
Figure 2
Figure 2. Family trees in patients with TP53 (A1), MMR gene mutations (B1-3) and variants in two predisposing genes (C1-3) (possibly including a TP53 or MMR mutation)
BC: breast cancer; OC: ovarian cancer, LiC: liver cancer, GyC: gynecological cancer, SyC: systemic cancer, PaC: pancreatic cancer, CeC: cervical cancer, PrC: prostate cancer, CRC: colorectal cancer, TeC: testis cancer, HoD: Hodgkin's disease, EC: endometrial cancer, Me: melanoma, LuC: lung cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Weissman SW, Weiss SM, Newlin AC. Genetic testing by cancer site ovary. Cancer J. 2012;18:320–7. - PubMed
    1. Van der Groep P, Van der Wall E, Van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol. 2011;34:71–88. - PMC - PubMed
    1. Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans GR, Chenevix-Trench G, et al. Gene-Panel Sequencing and the prediction of breast-Cancer Risk. N Engl J Med. 2015;372:2243–57. - PMC - PubMed
    1. Antoniou AC, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. - PMC - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed

MeSH terms

Substances